Related Experiment Video

Updated: May 4, 2026

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.5K

Novel drugs targeting the androgen receptor pathway in prostate cancer

Joaquin Mateo1, Alan Smith, Michael Ong

  • 1Drug Development Unit, Division of Cancer Therapeutics and Division of Clinical Studies, The Royal Marsden NHS Foundation Trust - The Institute of Cancer Research, Downs Road, Sutton, Surrey, SM2 5PT, UK.

Cancer Metastasis Reviews
|January 7, 2014
PubMed

Insights

Novel therapeutics for castration-resistant prostate cancer (CRPC) show survival benefits. Androgen receptor pathway drugs like abiraterone acetate and enzalutamide offer effective strategies despite resistance, improving CRPC treatment outcomes.

Area of Science:

  • Oncology
  • Pharmacology
  • Urology

Background:

  • Castration-resistant prostate cancer (CRPC) treatment has historically faced limited success.
  • Recent years have seen significant advancements with five novel therapeutics approved by the Food and Drug Administration.
  • These approvals are based on randomized phase III studies demonstrating a survival benefit for patients.

Purpose of the Study:

  • To review current data on novel androgen receptor (AR)-targeting drugs for CRPC.
  • To discuss the developmental status of these promising agents.
  • To explore the clinical challenges posed by the expanding therapeutic options for CRPC.

Main Methods:

  • Review of randomized phase III studies for novel CRPC therapeutics.
  • Analysis of drug mechanisms targeting the androgen receptor pathway, steroidogenesis, and post-receptor signaling.
  • Evaluation of clinical trial data for agents in development.

Main Results:

  • Abiraterone acetate and enzalutamide, targeting the AR pathway, have shown efficacy in CRPC.
  • These drugs demonstrate that targeting androgen signaling remains effective even with resistance mechanisms.
  • Several other agents targeting AR or related pathways are in clinical evaluation, showing promise.

Conclusions:

  • The development of novel AR-targeting drugs represents a revolution in CRPC treatment.
  • These advancements offer significant survival benefits for patients with advanced prostate cancer.
  • Optimal clinical utilization of these new agents presents challenges for healthcare providers.

More Related Videos

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients12:13

Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients

Published on: November 19, 2019

5.8K
Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses08:36

Prostate Organoid Cultures as Tools to Translate Genotypes and Mutational Profiles to Pharmacological Responses

Published on: October 24, 2019

9.7K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

1.4K
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
4.4K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
9.2K
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
613
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.3K